儿童重症流感病毒核酸转阴时间与神经氨酸酶抑制剂使用分析
该回顾性队列研究纳入79例PICU重症流感患儿,分析NA启动后病毒核酸转阴时间及停药策略。延迟转阴占比62%,>10 d组NA疗程更长、合并感染率和5 d后持续发热比例更高。发热组、核酸阳性组和双阴组在病死率及停药后48 h PRISM Ⅲ和pSOFA上无显著差异。
要点
- 重症流感患儿NA启动后延迟转阴比例较高,达62%。
- 核酸转阴>10 d者NA疗程显著延长,合并感染及持续发热更多。
- 核酸转阴或退热即可考虑停NA,但需个体化谨慎评估。
核心结论
- PICU重症流感患儿NA启动后病毒核酸延迟转阴比例较高,>10 d转阴者NA疗程显著延长。
- 核酸转阴或退热即可考虑停用NA,但需结合临床实际情况谨慎评估。
研究设计与样本
- 回顾性队列研究,纳入2019年11月至2024年7月北京儿童医院PICU收治的79例重症流感患儿。
- 纳入标准为NA连续使用≥72 h且每3~5天复查鼻咽拭子流感病毒核酸至转阴或出院。
主要发现
- 79例中男43例(54%)、女36例(46%),年龄4.6(2.3,7.7)岁。
- ≤5 d组30例(38%)、6~10 d组34例(43%)、>10 d组15例(19%),延迟转阴占比62%(49/79)。
- >10 d组NA使用时间更长,合并感染率及NA使用5 d后仍有发热比例均更高(均P<0.05)。
- ≤5 d组入PICU后4~5 d淋巴细胞减少占比最低(χ²=6.08,P<0.05)。
- 发热组(11例)、核酸组(26例)和双阴组(42例)住院病死率、停药后48 h PRISM Ⅲ和pSOFA差异均无统计学意义(均P>0.05)。
关键数值与推荐
- 延迟转阴定义为NA启动至核酸转阴>5 d,本研究延迟转阴占比62%(49/79)。
- 停药分组:发热组为发热且核酸阴性,核酸组为无发热但核酸阳性,双阴组为无发热且核酸阴性。
临床怎么用
- 对NA使用5 d后仍发热或合并感染者,应警惕病毒延迟转阴并评估NA疗程。
- 核酸转阴或退热后可考虑停用NA,但需结合患儿临床状态个体化判断。
局限性
- 为单中心回顾性队列研究,样本量79例,结果外推需谨慎。
- 原文未报告多因素回归分析,延迟转阴相关因素仅为组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To determine the time to influenza virus nucleic acid clearance and the treatment duration of neuraminidase inhibitors (NA) in children with severe influenza admitted to the pediatric intensive care unit (PICU) following NA initiation. This study further aimed to identify factors associated with delayed viral clearance and to evaluate the appropriateness of different NA discontinuation strategies. Methods: In this retrospective cohort study, we analyzed the clinical data of 79 children with severe influenza admitted to the PICU of Beijing Children's Hospital between November 2019 and July 2024. Inclusion criteria were continuous NA administration for ≥72 h after admission, and serial nasopharyngeal swab tests for influenza virus nucleic acid performed at 3 to 5 d intervals following NA initiation until clearance or discharge. Collected data included demographic characteristics, serial nucleic acid test results, body temperature, NA treatment duration, and in-hospital mortality were collected. Children were stratified into three groups based on time from NA initiation to viral nucleic acid clearance:≤5 d, 6-10 d, and >10 d, the latter 2 of which belong to the delayed clearance group. They were also categorized according to clinical status at NA discontinuation: the fever group (fever present, nucleic acid negative), the necleic acid-positive group (afebrile, nucleic acid positive) and the double-negative group (afebrile, nucleic acid negative). Select the appropriate statistical test from among the Chi-square test, Kruskal-Wallis H test, or Mann-Whitney U test to compare between-group differences in the following variables: duration of NA use, co-infection rate, proportion of patients with fever after 5 days of NA use, pediatric risk of mortality Ⅲ score (PRISM Ⅲ) at 48 h after NA discontinuation, pediatric sequential organ failure assessment score (pSOFA) , and in-hospital mortality rate. Results: Of the 79 children with severe influenza, 43 (54%) were male and 36 (46%) female. The age was 4.6 (2.3,7.7) years. Patients were categorized into the ≤5 d (30 cases), 6-10 d (34 cases), and >10 d (15 cases) groups. The overall proportion of delayed clearance was 62% (49/79). The >10 d group demonstrated a significantly longer duration of NA therapy, higher co-infection rate, and a greater proportion of patients with persistent fever after 5 d of treatment compared to the other groups (all P<0.05). The ≤5 d group had the lowest incidence of lymphopenia detected on days 4 and 5 after PICU admission (χ²=6.08, P<0.05). No significant differences were observed among the fever (11 cases), nucleic acid-positive (26 cases), and double-negative (42 cases) groups regarding in-hospital mortality, PRISM Ⅲ, or pSOFA at 48 h after NA discontinuation (P>0.05). Conclusions: A considerable proportion of children with severe influenza in the PICU experienced delayed viral clearance after NA initiation, which was associated with a longer treatment course, particularly in those requiring >10 d for clearance. Discontinuation of NA upon achieving virological clearance or defervescence may be considered, but this strategy requires careful clinical judgment tailored to the individual patient. 目的: 探讨儿童重症监护病房(PICU)内重症流行性感冒(简称流感)患儿给予神经氨酸酶抑制剂(NA)后流感病毒延迟转阴的相关影响因素及不同NA停药方法的合理性。 方法: 回顾性队列研究。收集2019年11月至2024年7月首都医科大学附属北京儿童医院PICU收治的NA连续使用≥72 h后每3~5天复查鼻咽拭子流感病毒核酸至转阴或出院的79例重症流感患儿的临床资料,包括患儿人口学信息、流感病毒核酸检测结果、体温、NA使用疗程、住院病死率等。根据开始使用NA至核酸转阴时间,将患儿分为≤5、6~10和>10 d组(>5 d为延迟转阴)。根据停用NA时是否发热及流感病毒核酸检测结果,分为发热组、核酸组、双阴组。分别选择χ2检验、Kruskal-Wallis H检验或Mann-Whitney U检验比较组间NA使用时间、合并感染率、NA使用5 d后仍有发热比例、停用NA后48 h第三代小儿死亡风险评分(PRISM Ⅲ)、儿童序贯器官衰竭评分(pSOFA)及住院病死率差异。 结果: 79例重症流感患儿中男43例(54%)、女36例(46%),年龄4.6(2.3,7.7)岁。≤5 d组30例(38%)、6~10 d组34例(43%)、>10 d组15例(19%),延迟转阴占比62%(49/79)。>10 d组NA使用时间更长,合并感染率、NA使用5 d后仍有发热比例均更高(均P<0.05)。≤5 d组入PICU后4~5 d淋巴细胞减少占比最低(χ2=6.08,P<0.05)。发热组(11例)、核酸组(26例)和双阴组(42例)住院病死率、停药后48 h PRISM Ⅲ和pSOFA分值差异均无统计学意义(均P>0.05)。 结论: 儿童重症监护病房内重症流感患儿使用NA后流感病毒核酸延迟转阴者比例较高,核酸转阴>10 d患儿NA使用时间显著延长。核酸转阴或停止发热即可考虑停用NA,但需谨慎且充分评估临床实际情况。.
引用
- Fang BL, Liu G, Qian SY, et al. [Analysis of viral nucleic acid negativity and neuraminidase inhibitor use in children with severe influenza]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41674420. doi:10.3760/cma.j.cn112140-20250804-00714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。